## 1 Preventing iatrogenic HCV infection: A quantitative risk assessment based on 2 observational data in an Egyptian hospital.

- Paul Henriot<sup>1,2</sup>, Wagida A. Anwar<sup>3</sup>, Maha El Gaafary<sup>3</sup>, Samia Abdo<sup>4</sup>, Mona Rafik<sup>4</sup>, Wafaa M. Hussein<sup>3</sup>, Dalia
   Sos<sup>3</sup>, Isis Magdy<sup>3</sup>, Kévin Jean<sup>1,2</sup>, Laura Temime<sup>1,2</sup>
- <sup>1</sup>MESuRS Laboratory, Conservatoire national des arts et métiers, 292 rue Saint-Martin, 75003, Paris
- 6 <sup>2</sup>PACRI Unit, Conservatoire national des arts et métiers / Institut Pasteur, France
- 7 <sup>3</sup>Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Ain Shams
- 8 University, Cairo, Egypt
- 9 <sup>4</sup> Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Contact information : Paul Henriot, Conservatoire national des arts et métiers (MESuRS Laboratory), 292 rue
 Saint-Martin, 75003, Paris. Email address: paul.henriot@lecnam.net

- Background: When compliance with infection control recommendations is non-optimal, hospitals may play an important role in hepatitis C (HCV) transmission. However, few studies have analysed HCV acquisition risk based on detailed empirical data in order to identify high-risk patient profiles or
- 15 transmission hotspots.
- 16 **Methods:** We used data from a prospective cohort study conducted on 500 patients in the internal
- 17 medicine and surgery departments of Ain Shams hospital (Cairo, Egypt). We first performed a
- 18 sequence analysis to describe patient trajectory profiles. Second, we estimated each patient's
- 19 individual risk of HCV acquisition based on ward-specific prevalence and procedures undergone. We
- 20 then identified within-hospital risk hotspots by computing ward-level risks. A beta regression model
- 21 was used to highlight upon-admission factors linked to HCV acquisition risk. Finally, ward-focused
- and patient-focused strategies were assessed for their ability to reduce HCV infection risk.
- 23 **Findings:** Sequence analysis identified 4 distinct patient profiles. The estimated HCV acquisition risk
- varied widely between patients and patient profiles. The risk was found to be higher in the internal
- 25 medicine hospital compared to the surgery hospital (median: 0.188% IQR [0.142%-0.235%] vs.
- 26 0.043%, CI 95%: [0.036%-0.050%]). Upon-admission risk predictors included source of admission,
- age, reason for hospitalization, and history of anti-schistosomiasis treatment, injection and
- endoscopy. Patient-focused interventions were found to be most effective to reduce HCV infectionrisk.
- Interpretation: Our results might help reduce the risk of HCV acquisition during hospitalisation in
   Egypt by targeting enhanced control measures to ward-level transmission hotspots and to at-risk
   patients identified upon admission.
- 33 **Funding:** INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hépatites)
- 34
- 35
- 20
- 36

37

## 38 **Research in context**

## 39 Evidence before this study

We searched PubMed for articles published between Jan 1, 1990 and Jul 05, 2022, and focused on risk assessment of iatrogenic HCV transmission. We used "Hepatitis C", "risk assessment", "model", "transmission", "hospital" and "patients" as keywords. We found five risk assessment articles, the oldest published in 1999 and the most recent in 2012. All of these studies were conducted in countries with low HCV prevalence and were only focusing on HCV transmission from patients to healthcare workers. In addition, the risks estimated within these studies were based on limited observations and did not take into account the procedure-specific transmission risk.

## 47 Added value of this study

Our study presents a probabilistic risk assessment of HCV transmission to patients within an Egyptian hospital using detailed empirical data. Based on these results, at-risk patient profiles and transmission hotspots were identified. In addition, we simulated ward-focused and patient-focused interventions in order to estimate the efficacy of a better equipment handling on the overall risk of HCV infection. Patient-focused interventions, for instance dedicating sterilized single-use material, were often found to be more efficient than ward-focused ones. However, targeting wards might be financially, logistically and ethically more acceptable.

## 55 Implications of all the available evidence

56 Considering the promising though insufficient results and high costs of the Egyptian HCV elimination 57 program, our results may help reduce HCV transmission at an hospital level. The score we built may 58 be used upon admission to detect high risk patients. In addition, enhanced control measures in 59 transmission hotspots may lead to an important risk reduction for hospitalized patients. Finally, this 60 work could be extended to other bloodborne pathogens such as Hepatitis B or HIV.

61

62

## 63 Introduction

Hepatitis C virus (HCV) is a bloodborne pathogen usually transmitted during iatrogenic procedures or
unsafe injections like drug use. Even though a direct-acting antiviral treatment is available, an
estimated 58 million people were still living with hepatitis C worldwide in 2019, with significant
morbidity and mortality consequences, mostly due to liver cirrhosis and hepatocellular carcinoma.<sup>1</sup>
Hence, preventing HCV transmission remains key in the fight against HCV in Egypt.

While the implementation of infection control measures has substantially reduced the risk of nosocomial HCV transmission, hospitals may still play an important role in the epidemic dynamics of HCV, due to potential exposure to infected patients and contaminated equipment.<sup>2,3</sup> This is particularly true in low-to-middle-income countries, such as Egypt.<sup>4,5</sup> However, HCV outbreaks in healthcare settings are seldom detected and investigated, so that the transmission routes often remain unknown.

A few studies quantified the HCV acquisition risk in hospitals.<sup>6,7,8,9,10</sup> However, these studies were mostly focused on the occupational risk to healthcare workers, most used data from the literature rather than actual observations, and none accounted for procedure-specific risk levels. In this

context, the first objective of this work is to assess the risk of nosocomial HCV infection for the patients hospitalized in an Egyptian hospital. To that aim, we propose a probabilistic risk assessment framework informed by detailed empirical data recently collected in this hospital. Based on this assessment, the second objective is then to identify transmission hotspots as well as at-risk patient profiles to better manage the HCV risk within the hospital.

83

## 84 Methods

## 85 Data and setting

Data was collected as part of a prospective cohort study (ANRS 12320 IMMHoTHep project, "Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C") conducted over a 6month period in 2017.<sup>11</sup> This study focused on patients hospitalized in the internal medicine and surgery departments of the Ain Shams University Hospital in Cairo, Egypt. These departments were further organized into 15 and ten wards, respectively.

Five hundred patients were included upon their admission to the hospital, either through the outpatient clinics or the emergency department. Their individual trajectories were then followed up over the course of their entire hospitalizations. This included information on their HCV status upon admission, their geographical movements between departments and wards within the hospital and the invasive procedures they underwent within these locations. Procedures performed were aggregated into 15 groups following expert opinion (Table 1). Further data about patients, such as demographic information, or end of study status, were collected upon admission and discharge<sup>11</sup>.

### 98 Ethical considerations

99 Ethical approval was obtained from the Institutional Review Board of the Faculty of Medicine of Ain100 Shams University and from the Sheffield University, School of Health and Related Research.

## 101 Trajectory analysis

102 To identify typical hospitalization profiles, we performed a sequence analysis based on patient 103 trajectories between seven locations (Surgery department, Internal medicine department, 104 Emergency room, ICU, Endoscopy building, MRI building, Outpatients clinic) within the hospital. Sequence analysis is a non-parametric approach to investigate and cluster longitudinal life course 105 data between individuals.<sup>12,13</sup> Here, sequences were composed of five-minute-long events over the 106 107 course of hospitalization, completed by the post-hospitalization status (i.e., deceased or discharged), 108 so that all trajectories had the same length as the longest one. Therefore, each sequence was 109 composed of at least two out of nine states, describing location within the hospital (seven states) and 110 post-hospitalization status (two states).

111 To compute differences between sequences, substitution and indel costs were calculated based on 112 the observed transition rates between the states previously defined. We used the optimal matching 113 (OM) method to compute the distance matrix between individual sequences.<sup>14</sup> Then, we compared 114 partitions built with the Ward's minimum variance method<sup>15</sup> using the Point Biserial Correlation 115 (PBC)<sup>16</sup> to find the optimal number of clusters.

116 All sequence analyses were performed using the R package TraMineR.<sup>17</sup>

## 117 **Per-procedure risk estimation**

We firstly estimated the risk of iatrogenic HCV infection following a procedure performed with contaminated equipment, for each of the 15 procedure types identified in the data. This was based on a previous meta-analysis studying the association between HCV infection and ten groups of iatrogenic procedures.<sup>18</sup> The 15 procedure types in the data were aggregated to match the groups considered in this meta-analysis (Table 1). Odds-ratio (OR) distributions were considered log-normal with mean equal to the average ORs and standard deviation derived from the associated confidence intervals.

The risk of getting HCV-infected through injection by contaminated equipment was then used as a reference to determine the other procedure-specific risks. Ross et al.<sup>7</sup> estimated this risk at 2.20% (plausible interval, 1%-9.2%). Here, we translated this as a PERT-distributed<sup>19</sup> risk distribution, with a median of 2.20% and an analytically calculated mode of 1.23% (Text S1):

129 
$$Risk_{injection} \sim PERT(1, 1 \cdot 23, 9 \cdot 2)$$

130 The procedure-specific risk of HCV infection due to contaminated equipment was calculated for each

131 procedure p as the ratio between the OR of this procedure (denoted  $OR_p$ ) and the injection OR,

132 multiplied by the risk due to injection with contaminated equipment, as follows:

$$Risk_p = \frac{OR_p}{OR_{injection}} \times Risk_{injection}$$

133

#### 134 Individual risk assessment

135 For each patient, the cumulative risk of HCV acquisition over the entire hospitalisation was computed

136 from the within-hospital individual trajectory, the ward-specific HCV prevalence and procedure-

137 associated risks, as follows:

$$R = 1 - \prod_{i=1}^{n} \prod_{j=1}^{m_i} (1 - r_{j,p} \times P_i \times (1 - A))$$

138 where *n* is the total number of wards visited by the patient,  $m_i$  the total number of procedures 139 undergone by the patient in ward *i*,  $r_{j,p}$  the risk of HCV acquisition while undergoing the  $j^{th}$ 140 procedure if the equipment is contaminated, A the probability of proper equipment handling (i.e., 141 equipment decontamination or use of disposable equipment) and  $P_i$  the HCV prevalence in ward *i*.

142 The risk  $r_{i,p}$  was computed as described in the previous section, based on the procedure type p. The ward-specific prevalence  $P_i$ , was used as a proxy of the ward-specific probability of medical 143 144 equipment being contaminated by HCV prior to infection control procedures. It was considered to be 145 constant over time and equal to the proportion of HCV-positive patients among all patients that 146 passed through ward i in our database. For simplicity, the probability of correct infection control in 147 equipment handling was assumed independent of the procedure type. Syringe reuse was taken as a proxy to estimate this probability at 97%, based on a study by Anwar et al.<sup>20</sup> which found that 3% of 148 nurses from two hospital departments in Egypt and Saudi Arabia reused syringes between patients. 149

Finally, to maximize statistical power in the identification of hotspots and at-risk profiles, we performed this individual risk assessment using the data from all 500 patients included in the IMMHoTHep study, irrespective of their HCV status upon admission, even though in reality the initially HCV-positive patients were not at-risk.

## 154 Ward-level risk assessment for hotspot identification

To determine the risk of HCV infection associated with each ward in the internal medicine and surgery departments, we calculated for each patient the risk of getting infected through invasive procedures undergone within each unique ward (based on subsets of their trajectories), as in the previous subsection. The distribution of a ward-specific risk was composed of the average risks of all patients visiting it. To shed light on the components of this risk, the ward-level HCV prevalence and average number of procedures per patient and procedure group were also calculated.

## 161 Statistical analyses of patient-level determinants of the HCV infection risk

162 We investigated differences between the clusters identified through the patient trajectory analyses 163 across: (i) age, HCV infection risk, duration of hospitalization and average number of procedures per 164 patient as quantitative variables; and (ii) gender, education level, marital status, source of admission, 165 source of admission, patient localization, history of hospitalization, hospitalization reason and status 166 at the end of follow-up as categorical variables. Differences were computed using the  $\chi^2$  test for 167 qualitative variables and the Kruskal-Wallis test for quantitative variables.

168 We performed a beta regression to identify upon-admission factors associated with nosocomial HCV 169 risk.<sup>21</sup> As some patients had an infection risk equal to 0, data was transformed following this formula: 170  $y' = (y \times (n - 1) + 0.5)/n$ , where y is the risk data and n is the sample size.<sup>22</sup> Explanatory 171 variables included: age, gender, source of admission, patient localization, history of hospitalization, 172 and hospitalization reason, previous anti-schistosomiasis treatment and history of multiple invasive 173 procedures. A backward selection was performed to discriminate the best model based on the Akaike 174 information criterion (AIC).

175 Finally, using logistic regression, we assessed the capacity of a score based on the variables appearing 176 in the best beta regression model to identify at-high-risk patients. We defined high-risk patients as those belonging to the upper 25% of the risk distribution (over the 75<sup>th</sup> percentile). The training data 177 178 was composed of 70% of the entire dataset whereas the other 30% was used for the testing dataset. 179 If data unbalance was detected, up-sampling was used to equalise sample sizes for both groups. 180 Cross-validation was performed over 50 folds. Area under the ROC curve (AUC), specificity and sensitivity were computed using the R packages caret<sup>23</sup> and Mleval<sup>24</sup>. A sensitivity analysis was 181 performed on the cut-off for dichotomization; for each case, the Informedness<sup>25</sup> metric was 182 183 calculated and considered as a proxy of the guality of the model.

#### 184 Assessment of patient and ward-focused strategies

185 We assessed the potential effectiveness of two strategies on the reduction of the HCV infection risk:

i) A patient-focused strategy, assuming the probability A of proper equipment handling to be 1 for
the most at-risk patients, selected following two sub-strategies: a) randomly (Random-selection) and
b) using upon admission the calculated score based on our beta regression model. Here all potential
HCV-positive patients within the most-at risk group were considered HCV-negative upon admission,
so that they did not impact the risk of other patients visiting the same wards. Strategies targeted at
100, 125, 150, 175 and 200 at-risk patients among 500 were explored.

ii) A ward-focused intervention, assuming the probability A of proper equipment handling to be 1
within the most at-risk wards. Wards were ranked from higher to lower risk and the number of
targeted wards was chosen based on the cumulative number of patients visiting at least once these
particular wards, so that the total number of patients was the closest possible to the number of
patients targeted in the corresponding patient-focused scenario.

197

#### 198 Results

#### 199 **Patient trajectory description**

200 The sequence analysis identified four groups of patients (Fig.1, Supp. Fig. S1). Their sizes were 201 heterogeneous (356, 54, 14 and 76 patients, respectively). Group one (the largest one) included 202 patients with a short hospital stay in internal medicine or surgery, Groups two and four represented 203 patients with intermediate lengths of stay in surgery and internal medicine, respectively, and Group 204 three was composed of patients with long stays in internal medicine. In the latter, 36% of patients 205 were deceased at the end of follow-up. Patients in Group three were older than in the other groups 206 (median: 64 years old, IQR [46-67]), had longer hospital stays (20.4 days [17.5-23.2]) and underwent 207 more invasive procedures (median: 43 [15 – 77]) (Table S1).

## 208 HCV infection risk assessment

209The estimated per-procedure median risk of HCV infection due to contaminated equipment ranged210from 1.961%% [IQR 1.339% - 2.923%] for endoscopy up to 3.750% [IQR 2.566% - 5.584%] for wound211care (Supp. Fig. S1).

212 The median patient HCV infection risk over the entire database was 0.043% [0.026%-0.093%] (Mean:

213 0·114%, IC95% [0·091%-0·137%]). This risk differed significantly between patient groups (p<0·001),

with a greater risk of getting HCV infected in group 3 (median: 0.470%, IQR [0.081% - 0.823%]) (Supp.
Table S1).

## 216 Ward-level risk assessment and hotspot identification

217 Overall, the risk of HCV infection was higher in the internal medicine hospital compared to the 218 surgery hospital (0.043%, CI 95%: [0.036%-0.050%] vs. 0.188% [0.142%-0.235%], t.test p< $3.62*10^{-9}$ ).

219 Within internal medicine, HCV prevalence was found highest in the tropical medicine ward (50% CI 220 95% [32·100% - 67·900%]), followed by the GIT (31% [15·620%-45·980%]), and geriatric wards (20% 221 [0%-55.060%]). Conversely, the average number of procedures within the ER ICU ward was found to 222 be the highest with 33.1 acts, followed by the geriatric ward with 21.6 acts, while the tropical 223 medicine and GIT wards only held the 9th and 10th places among the 15 wards, with 10.45 and 8.24 224 procedures per patient on average. The median estimated risk of HCV infection was highest in the 225 geriatric ward (0.621% IQR [0.114%-0.649%], mean: 0.431%) represented by 5 patients, followed by 226 the ward of tropical medicine (0.271 % [0.146 %- 0.599%], mean: 2.850%), represented by 30 227 patients and ER ICU ward (0.242% IQR [0.180%-0.811%], mean: 0.474%), represented by 11 patients 228 (Fig. 2).

229 Within surgery (Fig. 3), HCV prevalence was high within the urosurgery, orthopaedics, and 230 neurosurgery wards, at 20% [0%-55.060%], 57.140% [20.480% -93.800%] and 5.330% [0% - 15.790%]. 231 The ICU ward was associated with the highest number of invasive acts, with an average of 12.75 232 procedures per patient. Within the orthopaedics and neurosurgery wards, patients underwent 8.5 233 and 7.4 invasive procedures on average, respectively, and only 1.4 in the urosurgery ward. The 234 highest risk was found in the urosurgery ward (0.045% IQR [0.044%- 0.046%], mean: 0.101%), but 235 only 7 patients visited it. This was followed by the orthopaedics (0.037 % IQR [0.024 %- 0.053 %]. 236 mean: 0.046%) and the neurosurgery (0.021% IQR [0.021 %- 0.089 %], mean: 0.165%) wards, 237 represented by 75 and 6 patients respectively.

## 238 Identification of at-risk patient profiles upon admission

The best beta regression model explaining the patient HCV infection risk from upon-admission variables is described in Table 2. The hospitalisation cause came out as a key driver of HCV risk, reflecting the higher risk in internal medicine patients, as well as a particularly elevated risk in patients with liver or gastro-intestinal (GIT) complaints. In addition, patients with a history of antischistosomiasis treatment were found at higher risk of HCV infection. Other variables selected in the best model were the source of admission and age, with a higher risk in patients admitted via the emergency room or older; and a history of injection or endoscopy.

A score based on these explanatory variables allowed to discriminate high-risk patients upon admission. The calculated AUC was 0.79 (95% CI: [0.71-0.87]) with a sensitivity of 0.73 [0.65-0.79], and a specificity of 0.68 [0.54-0.79] (Table S3). Based on a sensitivity analysis, we found that using a cut-off at the 90<sup>th</sup> percentile of the overall distribution led to the best logistic regression based on the Informedness criteria (Table S3).

251

## 252 Assessment of patient and ward-focused strategies

All simulated interventions led to at least a two-fold reduction of the overall risk, except those based on randomly selecting patients (Fig. 4, Supp. Table S2). In addition, patient-focused interventions were generally found to be more effective than ward-focused (Fig. 4, Supp. Table S2). Nevertheless, for interventions targeting less than 100 patients (20% of patients), targeting the most at-risk wards (i.e., Rheumatology, Tropical medicine, ER ICU, GIT and endoscopy) was more efficient at reducing the risk than score-based patient targeting (reduction of 52.51% vs. 56.02%).

259

#### 260 Discussion

This study aimed at better understanding patient trajectories within an Egyptian hospital to help manage the HCV infection risk. Our work was based on data collected on 500 patients within Ain Shams hospital, Egypt, and on a meta-analysis investigating the risk of HCV infection for multiple hospital-based procedures,<sup>18</sup> from which we computed HCV infection risks for all patients over the course of their hospitalisation.

266 Due to high uncertainty, notably on per-procedure infection control practices, our risk estimates 267 should be considered relatively, rather than focusing on their absolute values. For instance, we 268 propose a prioritisation of wards in terms of HCV infection risk in the surgery and internal medicine 269 departments. In particular, we found that the internal medicine department is the most at-risk of 270 HCV infection, with the geriatric, tropical and endoscopy wards within this department identified as 271 potential "hotspots". This is consistent with a previous risk assessment study conducted in a German 272 hospital in 2008 in which the highest risk of bloodborne pathogen infection for HCW was within the internal medicine departments.<sup>25</sup> 273

274 Several data-related and methodological limitations could be highlighted in our study.

First, we were limited by our data and had few observations of patients for multiple wards. In particular, the highest estimated risks were observed in wards that received a low number of patients (Neurosurgery and geriatric). In future studies, investigating these specific risks based on more patient visits might give more accurate estimates of the corresponding ward-level HCV infection risks.

Second, we did not have access to HCV status upon patient discharge. A study assessing the HCV status after hospitalisation in addition to the HCV status upon admission would be needed to really quantify the risk of getting HCV infected during a hospital stay from data. However, we believe that the analyses we performed, based on detailed data on patient trajectories and per-procedure risk ranking, do provide valid conclusions in terms of the identification of possible hotspots and at-risk patient profiles within the hospital.

Third, we only accounted for transmission between patients within the same ward and did not investigate potential transmission from healthcare workers to patients, which can be an important HCV gateway.<sup>26</sup> This may have led us to under-estimate all the HCV acquisition risks, but should not have affected the prioritisation we propose in terms of geographical hotspots and patient profiles upon admission. Indeed, an earlier study performed in the same hospital on a larger staff population confirmed that HCV RNA positive healthcare workers were very rare, and that highest proportions of HCV-infected healthcare workers were found in the internal medicine department.<sup>27</sup>

Fourth, our beta-regression model identified several upon-admission variables as associated with the risk of HCV infection during hospitalization. These associations should not be interpreted as causal. For example, patients with a history of anti-schistosomiasis treatment were found to be more at risk of HCV infection, possibly reflecting the high prevalence among other patients they are exposed to.

While HCV prevalence varies widely between countries, Egypt has historically been the most affected 297 298 country worldwide, with an HCV prevalence still over 10% in the adult population in the mid 2010's<sup>29</sup>. The scaling-up of DAA treatments has temporarily yielded the hope that a large test-and-treat 299 strategy could be sufficient to eliminate the epidemics.<sup>29</sup> In this context, Egypt launched an ambitious 300 301 national treatment programme in 2014, followed by an intensive screening and treatment 302 programme in 2018, with the objective of eliminating HCV within the country by 2021. In 2018 and 2019, almost 50 million Egyptian residents were screened (80% of the adult population), resulting in 303 an HCV seroprevalence reduced to 4.6% in the adult population.<sup>30</sup> The number of HCV contaminated 304 individuals registered for treatment decreased after the first treatment phase and became 305 306 insufficient to reach the elimination target on time.<sup>31</sup> Despite promising results, elimination was not achieved and the cost of this program was estimated at more than 2 billion US dollars.<sup>29</sup> Hence, 307 articulating primary HCV prevention, especially in healthcare settings,<sup>32</sup> together with treatment and 308 309 cure remain remains key.

310 In a context of limited budget and human resources, this work may help better manage the HCV risk 311 within Egyptian hospitals in two ways. First, infection control could be reinforced locally in the 312 hotspots we identified. This could for instance imply systematic HCV screening for patients newly 313 admitted to these specific wards, hiring of dedicated hygiene personnel within these wards, or 314 allocation of the available disposable equipment to these wards. Second, the score we proposed 315 could be systematically computed upon admission for all newly admitted patients. Those identified 316 as at high risk could then be "flagged" for reinforced precautions over the course of their 317 hospitalisation. When comparing such ward-focused and patient-focused strategies, we found that 318 interventions targeted at identified at-risk patients upon admission were most effective. However, 319 interventions focused on ward hotspots also allowed to reduce the risk more than two-fold and may 320 in practice prove both easier to implement logistically and more acceptable from an ethical point of 321 view. In addition, when hospital resources only allowed to target less than 20% of patients for 322 reinforced infection control, ward-focused interventions were actually most effective.

In addition, the framework we developed could also be extended to assess and manage iatrogenic
 HCV risks in other hospitals or risks associated with other blood-borne pathogens such as HIV or HBV.

This would require, in the first case, the collection of data on patient trajectories similar to the MMHoTHep data in other hospitals; and in the second case, estimates of the per-procedure

327 infection risks associated with these other pathogens.

328 Finally, in future work, the detailed data we collected on patient trajectories and invasive procedures

329 could be used to inform mechanistic models simulating dynamically the transmission of HCV or other

330 blood-borne pathogens within the hospital. Such models would allow to assess the impact of

potential control measures in a more accurate way than the very simplified assessment proposed here.

## 333 Contributors

PH, KJ and LT conceived the study, wrote the protocol and data analysis plan. PH did the analyses.
Data curation was carried by MEG, MR, WMH, IM and LT. PH wrote the first draft of the report with
input from LT, KJ, WAA, MEG, SA, MR, WMH, DS and IM. All authors had full access to all the data in
the study and had final responsibility for the decision to submit for publication.

## 338 **Declaration of interests**

339 We declare no competing interests.

# 340 Acknowledgements

This study was funded by INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hépatites), grant
 number 12320 B115.

- 343
- 344
- 345
- 346
- 347
- 348
- 349
- 350
- 351
- 352
- 353
- 354
- 355
- 356
- <u>---</u>
- 357
- 358
- 359

360		
361		
362		
363		
364	Refere	nces
365		
366 367 368 369 370	1.	World Health Organization. Regional Office for Europe. Consultation on the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections (STIs), 2022–2030: virtual meeting report: Copenhagen, Denmark and online 16–17 June 2021. Copenhagen: World Health Organization. Regional Office for Europe, 2022.
371 372 373	2.	Johannessen I, Danial J, Smith DB, <i>et al.</i> Molecular and epidemiological evidence of patient- to-patient hepatitis C virus transmission in a Scottish emergency department. <i>Journal of</i> <i>Hospital Infection</i> 2018; <b>98</b> : 412–8.
374		
375 376 377 378 379	3.	Mazzucco W, Chiara di Maio V, Bronte F, <i>et al.</i> Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy. <i>Journal of Hospital Infection</i> 2021; <b>115</b> : 51–8.
380 381 382	4.	Senosy SA, El Shabrawy EM. Hepatitis C virus in patients on regular hemodialysis in Beni-Suef Governorate, Egypt: Journal of the Egyptian Public Health Association 2016; <b>91</b> : 86–9.
383 384 385 386	5.	Metwally A, Mohsen A, Saleh R, <i>et al.</i> Prioritizing High-Risk Practices and Exploring New Emerging Ones Associated With Hepatitis C Virus Infection in Egypt. <i>Iran J Public Health</i> 2014; <b>43</b> : 1385–94.
387 388 389	6.	Yazdanpanah Y, Boëlle P-Y, Carrat F, Guiguet M, Abiteboul D, Valleron A-J. Risk of hepatitis C virus transmission to surgeons and nurses from infected patients : model-based estimates in France. <i>Journal of Hepatology</i> 1999; <b>30</b> : 765–9.
390		
391 392 393 394 395	7.	Ross RS, Viazov S, Roggendorf M. Risk of Hepatitis C Transmission From Infected Medical Staff to Patients: Model-Based Calculations for Surgical Settings. <i>Arch Intern Med</i> 2000; <b>160</b> : 2313.
396 397 398 399	8.	Thorburn D. Risk of hepatitis C virus transmission from patients to surgeons: model based on an unlinked anonymous study of hepatitis C virus prevalence in hospital patients in Glasgow. <i>Gut</i> 2003; <b>52</b> : 1333–8.
400 401 402 403	9.	Rischitelli G, Lasarev M, McCauley L. Career Risk of Hepatitis C Virus Infection Among U.S. Emergency Medical and Public Safety Workers: <i>Journal of Occupational and Environmental Medicine</i> 2005; <b>47</b> : 1174–81.

404 10. Gańczak M, Szczeniowski A, Jurewicz A, Karakiewicz B, Szych Z. Model-based estimates of 405 the risk of HCV transmission from infected patients to gynaecologic and obstetric staff. 406 Przegl Epidemiol 2012; 66: 437–43. 407 408 409 11. Anwar WA, El Gaafary M, Girgis SA, et al. Hepatitis C virus infection and risk factors among patients and health-care workers of Ain Shams University hospitals, Cairo, Egypt. PLoS ONE 410 411 2021; 16: e0246836. 412 413 12. Piccarreta R, Studer M. Holistic analysis of the life course: Methodological challenges and 414 new perspectives. Advances in Life Course Research 2019; **41**: 100251. 415 416 13. Gosselin A, Desgrées du Loû A, Lelièvre E. How to use sequence analysis for life course 417 epidemiology? An example on HIV-positive Sub-Saharan migrants in France. J Epidemiol 418 *Community Health* 2018; **72**: 507–12. 419 420 421 14. Abbott A, Tsay A. Sequence Analysis and Optimal Matching Methods in Sociology: Review 422 and Prospect. Sociological Methods & Research 2000; 29: 3-33. 423 424 15. Ward JH. Hierarchical Grouping to Optimize an Objective Function. Journal of the American 425 Statistical Association 1963; 58: 236-44. 426 427 16. Kornbrot D. Point Biserial Correlation. In: Balakrishnan N, Colton T, Everitt B, Piegorsch W, 428 Ruggeri F, Teugels JL, eds. Wiley StatsRef: Statistics Reference Online, 1st edn. Wiley, 2014. 429 17. Gabadinho A, Ritschard G, Müller N, Studer M (2011). "Analyzing and Visualizing State 430 431 Sequences in R with TraMineR." Journal of Statistical Software, 40(4), 1–37. 432 433 18. Henriot P, Castry M, Luong Nguyen LB, Shimakawa Y, Jean K, Temime L. Meta-analysis: Risk 434 of hepatitis C virus infection associated with hospital-based invasive procedures. Aliment 435 Pharmacol Ther., 2022 (Published ahead of print). doi:10.1111/apt.17106 436 437 19. Clark CE. Letter to the Editor-The PERT Model for the Distribution of an Activity Time. Operations Research 1962; 10: 405-6. 438 439 440 20. Anwar MM, Mohamed Lotfy AA, Alrashidy AA. Safe injection awareness and practices among 441 nursing staff in an Egyptian and a Saudi hospital. J Egypt Public Health Assoc 2019; 94: 21. 442 443 21. Ferrari S, Cribari-Neto F. Beta Regression for Modelling Rates and Proportions. Journal of 444 Applied Statistics 2004; **31**: 799–815. 445 446 22. Smithson M, Verkuilen J. A better lemon squeezer? Maximum-likelihood regression with 447 beta-distributed dependent variables. Psychological Methods 2006; 11: 54-71. 448 449 23. Kuhn M. Building Predictive Models in *R* Using the caret Package. J Stat Soft 2008; 28. 450 451 24. Christopher R John (2020). MLeval: Machine Learning Model Evaluation. R package version 452 0.3. https://CRAN.R-project.org/package=MLeval (accessed Apr 4 2022) 453 454 25. Youden WJ. Index for rating diagnostic tests. *Cancer* 1950; **3**: 32–5.


455		
456	26	. Wicker S, Cinatl J, Berger A, Doerr HW, Gottschalk R, Rabenau HF. Determination of risk of
457		infection with blood-borne pathogens following a needlestick injury in hospital workers. Ann
458		Occup Hyg. 2008;52(7):615-622. doi:10.1093/annhyg/men044
459		
460	27.	. Okasha O., Munier A., Delarocque Astagneau,E., El Houssinie, M., Rafik, M. et al. (2015).
461		Hepatitis C virus infection and risk factors in health-care workers at Ain Shams University
462		Hospitals, Cairo, Egypt. EMHJ-Eastern Mediterranean Health Journal, 21 (3), 199 - 212. World
463		Health Organization, Regional Office for the Eastern Mediterranean.
464		https://apps.who.int/iris/handle/10665/255088 (accessed June 10 2022)
465		
466	28	. Gomaa A, Allam N, Elsharkawy A, El Kassas M, Waked I. Hepatitis C infection in Egypt:
467		prevalence, impact and management strategies. <i>HMER</i> 2017; <b>Volume 9</b> : 17–25.
468		
469	29	. Schwander B, Feldstein J, Sulo S, Gonzalez L, ElShishiney G, Hassany M. Pursuing Elimination
470		of Hepatitis C in Egypt: Cost-Effectiveness and Economic Evaluation of a Country-Wide
471		Program. Infect Dis Ther 2022; <b>11</b> : 1193–203.
472		
473	30.	. Waked I, Esmat G, Elsharkawy A, et al. Screening and Treatment Program to Eliminate
474		Hepatitis C in Egypt. <i>N Engl J Med</i> 2020; <b>382</b> : 1166–74.
475		
476	31.	. Waked I. Case study of hepatitis C virus control in Egypt: impact of access program. Antiviral
477		Therapy 2022; <b>27</b> : 1-6.
478		
479	32.	. Mostafa A, El-Sayed MH, El Kassas M, Elhamamsy M, Elsisi GH. Safety-Engineered Syringes:
480		An Intervention to Decrease Hepatitis C Burden in Developing Countries-A Cost-
481		Effectiveness Analysis From Egypt. Value in Health Regional Issues 2019; <b>19</b> : 51–8.
482		
483		
484		
485		
486		
487		
488		
489		

## 490 FIGURES AND TABLES

491

Table 1. Odds-ratios (OR) of HCV infection associated with exposure to iatrogenic procedures, based
 on a previously published meta-analysis<sup>18</sup>. The 15 procedure types in the IMMHoTHep data (second
 column) are aggregated into 8 of the 10 procedure groups defined in the meta-analysis and sorted
 from higher to lower risk. No procedures from the remaining 2 groups defined in the meta-analysis
 (dental care and transplantation) were observed in the IMMHoTHep data.

Procedure groups in meta-analysis	Procedures in data	OR [CI 95%]
Wound care	Stitches, Wound dressing	2.83 [1.85-4.32]
Blood transfusion	Blood transfusion	2.60 [2.09-3.22]
IV - Catheter	Intravenous, Cardiac catheter	2.42 [1.68-3.51]
Surgery	Surgery	2.30 [1.77-3.00]
Other procedures	Other invasive procedures, drainage catheter	2.28 [1.43-3.64]
Haemodialysis	Dialysis	2.02 [0.98-4.17]
Injection	Injection, Blood glucose, Blood sample	1.67 [1.17-2.38]
Endoscopy	Endoscopy, Endotracheal intubation, gastric lavage	1.48 [0.95-2.3]




497

498

499

**Figure 1.** Chronograms for each of the four clusters of patients identified after sequence analysis. Dotted lines represent the average length of stay for each group of patients.



500

Figure 2. Panel of ward characteristics for each ward in the Internal medicine hospital. (A) HCV
 prevalence in each ward with their associated 95% confidence intervals. (B) Average number of
 procedures per patient. Procedure types are represented from the high-risk ones to the low-risk ones
 (from left to right). (C) Boxplots of average ward-specific risk of HCV infection, coloured according to

505 the number of patients visiting these wards. Mean values are represented by purple diamond dots.





Figure 3. Panel of ward characteristics for each ward in the Surgery hospital. (A) HCV prevalence in each ward with their associated 95% confidence intervals. (B) Average number of procedures per patient. Procedure types are represented from the high-risk ones to the lowrisk ones (from left to right). (C) Boxplots of average ward-specific risk of HCV infection, coloured according to the number of patients visiting these wards. Mean values are represented by purple diamond dots. Three wards are not represented because no patients underwent invasive procedures within them.

#### 528 **Table 2.** Result of the multivariate beta-regression analysis.

		_	_
Characteristic	β	Std. Error	p-value
Source of admission			
Outpatient clinic	-	-	
Emergency room	0.081	0.051	0.114
Age	0.003	0.002	0.065
Reason for hospitalisation			
General surgery	-	-	
Special surgery	0.064	0.075	0.395
General IM	0.276	0.089	<0.01**
Special IM	0.195	0.068	<0.01**
Liver/ GIT complaint	0.443	0.092	<0.001***
Previous anti-			
schistosomiasis treatment			
No / Doesn't remember	-	-	-
Yes	0.169	0.084	0.043*
Previous injection			
No / Doesn't remember	-	-	-
Yes	0.097	0.052	0.062
Previous endoscopy			
No / Doesn't remember	-	-	-
Yes	0.118	0.072	0.102

#### 529

IM: internal medicine. GIT: gastro-intestinal



530

Figure 4. Effect of simulated intervention on the overall risk of HCV infection during hospitalization.
Error bars correspond to the 95% confidence intervals of the mean. Labels under bars correspond to
the number of concerned patients for a given intervention for the five sub-scenarios considered in

534 the analysis.